Type 2 Inflammation in Common Pruritic Skin Diseases

Summary
The pathophysiology of itch is complex and interacts with the type 2 inflammation that underlies common pruritic skin diseases, such as atopic dermatitis (AD), chronic spontaneous urticaria (CSU), and prurigo nodularis (PN). As one of the most commonly reported symptoms by patients seen in dermatology and primary care, itch can pose a diagnostic dilemma for clinicians—especially in patients of color, whose presentations may differ from those with lighter skin tones. In this webcast, dermatology experts Brian Kim, MD, and Mona Shahriari, MD, examine itch at the cellular as well as phenotypic level, describing key inflammatory mediators involved in the pathophysiology of pruritic skin diseases, and differentiating disease presentation in patients of every skin tone.

Learning Objectives
Upon completion of this activity, learners should be able to: 

• Recognize and differentiate common pruritic skin disease presentations across skin types
• Summarize the clinical features, comorbidities, and diagnostic evaluation of common pruritic skin diseases
• Describe the pathophysiologic mechanisms of itch and type 2 inflammation underlying common pruritic skin diseases

Faculty

Brian S. Kim, MD, MTR
Sol and Clara Kest Professor
Vice Chair of Research
Site Chair, Mount Sinai West and Morningside
Director, Mark Lebwohl Center for Neuroinflammation and Sensation
Lead, Allen Discovery Center for Neuroimmune Interactions
The Kimberly and Eric J. Waldman Department of Dermatology
Precision Immunology Institute
Friedman Brain Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Mona Shahriari, MD
Assistant Clinical Professor of Dermatology
Yale University School of Medicine
Associate Director of Clinical Trials, CCD Research PLLC
Partner at Central CT Dermatology
Cromwell, CT

Moderator

Brad P. Glick, DO, MPH, FAAD
Member, AAD Board of Directors
Dermatology Residency Director
Larkin Health System
PI, GSI Clinical Research
ASDS Advocacy Ambassador
Miami, FL

Nurse Planner and Peer Reviewer
Angela Golden, FNP-C, DNP, FAANP, FOMA
Director, NP Obesity Treatment Clinic
Flagstaff, AZ
Director, NP from Home
Munds Park, AZ

Bernadette Makar, MSN, NP
Saint Peter’s University Hospital
Coordinator House Service Program
New Brunswick, NJ
Rutgers University
Clinical Adjunct
Newark, NJ

Provided By 
The National Association for Continuing Education

NACE Accreditation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NACE Credit Designation Statement
The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NACE AANP Provider
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com 

How to obtain the CME Certificate

1. Register for the course at mycme.com.

2. Listen to the content.

3. Complete and submit the post-assessment and evaluation.

4. A minimum passing score of 75% must be earned on the post-assessment in order to complete the CME/CE activity.

5. Print your CME/CE certificate.

Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

For assistance regarding completing the course or obtaining your certificate, please contact myCME at cme.questions@haymarketmedical.com.

Privacy Policy
myCME privacy policy

NACE and Haymarket Medical Education do not share the names and contact information of learners with any ineligible companies.

Policy on Faculty and Provider Disclosure
Accredited education provided by the National Association for Continuing Education (NACE) must demonstrate balance, independence, objectivity, and scientific rigor. All individuals in a position to influence content of NACE accredited education, are required to disclose all financial relationships with ineligible companies within the previous 24-month period, regardless of relevance to the education. All relevant financial relationships and potential conflicts of interest have been mitigated.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Summary of Individual Disclosures
Brad Glick has disclosed the following financial relationships:

• Investigator: AbbVie, AstraZeneca, Amgen, Arcutis, Bellus Medical, Galderma, Sun Pharma, Lilly, Dermavant Sciences, Bristol Myers Squibb, Nimbus Lakshmi, Inc., Cara Therapeutics, Dermira, Inc., ChemoCentryx, Brickell Biotech, CorEvitas, PROSE
• Advisor: AbbVie, Amgen, Arcutis, Janssen, Galderma, Sun Pharma, Leo Pharma, Lilly, Novartis, Dermavant Sciences, Incyte, Bristol Myers Squibb, Dermira, Inc., Sanofi/Genzyme, Regeneron, Pfizer, Ortho Dermatologics, UCB, EPI/Novan
• Speaker: AbbVie, Amgen, Arcutis, Janssen, Sun Pharma, Lilly, Novartis, Dermavant Sciences, Incyte, Bristol Myers Squibb, Dermira, Inc., Sanofi/Genzyme, Regeneron, Pfizer, Ortho Dermatologics, UCB, EPI/Novan

All his disclosures are related to dermatology.

Angela Golden has disclosed the following financial relationships:

• Consultant: Novo Nordisk (obesity), Lilly (obesity), Acella (thyroid), Currax (obesity), Boehringer Ingelheim (obesity), WW (obesity), Gelesis (obesity - relationship has ended)

• Speaker: Novo Nordisk (obesity), Lilly (obesity), Acella (thyroid), Currax (obesity)

• Receipt of Royalty: Springer (obesity - relationship has ended), Amazon (fiction)

Brian Kim has disclosed the following financial relationships:

• Consultant: 23andMe, AbbVie, Amgen, Cara Therapeutics, Clexio Biosciences, Eli Lilly and Company, Escient Pharmaceuticals, Evommune, Galderma, LEO Pharma, Micreos, Pfizer, Recens Medical, Regeneron, Sanofi, Septerna, Teva, Trevi Therapeutics, and Triveni Bio
• Stockholder: Recens Medical
• Patent for the use of JAK1 inhibitors for chronic pruritus, patent pending for the use of JAK inhibitors for interstitial cystitis.

All his disclosures are related to dermatology

Bernadette Makar has no relevant conflicts of interest with any ACCME-defined commercial interest.

Mona Shahriari has disclosed the following financial relationships:

• Consultant and Advisor: Abbvie (AD, HS, PsO), Amgen (PsO), Arcutis (PsO, AD), Bristol Myers Squibb (PsO), Dermavant (PsO, AD), Galderma (AD, PN), Janssen (PsO), Leo Pharma (AD), Lilly USA (PsO, AD, AA), Pfizer (AD), Novartis (HS), Sanofi-Genzyme (AD), Regeneron (AD), UCB (PsO)

• Speaker: Abbvie (AD, PsO), Arcutis (PsO), Bristol Myers Squibb (PsO), Lilly USA (PsO, Areata), Janssen (PsO), Dermavant (PsO), Pfizer (Areata), UCB (PsO)

• Investigator: CorEvitas (psoriasis, atopic dermatitis, registry)

• Contracted Research: CorEvitas (psoriasis, atopic dermatitis, registry)

All of the relevant financial relationships listed for these individuals have been mitigated.

NACE staff and guest patient(s) (if applicable) have no relevant financial relationships to disclose.

Disclosure of Unlabeled/Investigational Uses of Products
The following CME/CE activity may include discussions on the use of off-label, investigational, and experimental use of medications, data presented in abstract form, and/or devices that may exceed their FDA-approved labeling. This data should be considered preliminary until published in a peer-reviewed journal.

NACE requires that all speakers disclose when a product is not labeled for the use under discussion. Participants should verify all information and data before treating patients or employing any therapies described in this or any educational activity and should consult the current manufacturers’ prescribing information.

Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NACE, Galderma, Sanofi and Regeneron Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact cme.questions@haymarketmedical.com.

Disclosure of Commercial Support
This educational activity is supported by educational grants from Sanofi and Regeneron Pharmaceuticals and by an educational grant from Galderma..